Daiichi Sankyo Company (TSE:4568) Wins EU Approval For Enhertu, Is The Stock A Bargain?
Daiichi Sankyo Company (TSE:4568) just cleared a key regulatory hurdle in Europe. The European Commission approved Enhertu with pertuzumab for first-line treatment of certain HER2 positive metastatic breast cancer patients.
Daiichi Sankyo Company’s latest share price of ¥2,772 comes after a mixed run, with the stock rising 10.86% on a 90 day share price return but falling 21.47% on a year to date share price basis and posting a 19.79% decline in 1 year total shareholder return. Recent regulatory wins and the court ruling therefore sit against a backdrop of longer term weakness, where momentum is only starting to rebuild.
Scan beyond Daiichi Sankyo Company and see how other oncology focused businesses are priced today with our curated list of 73 high quality undiscovered gems.
Daiichi Sankyo Company now trades at a sizeable discount to both analyst targets and some intrinsic estimates after this regulatory bounce. Is that a misplaced safety margin, or a fair reflection of the risks still on the table?
Most Popular Narrative: 33.1% Undervalued
Daiichi Sankyo Company’s widely followed narrative pegs fair value at ¥4,146, well above the latest close at ¥2,772, which puts the current pricing gap under the spotlight.
Pipeline depth in antibody-drug conjugates (ADCs) supported by ongoing R&D investment and multiple upcoming pivotal data readouts and regulatory submissions (e.g., for breast, gastric, lung, and gynecological cancers) positions the company to capture higher-margin opportunities as precision medicine gains traction, which could further boost future net margins and earnings.
Want to understand why this narrative supports a higher value for Daiichi Sankyo Company? The story leans heavily on compounding revenue expansion, steady margin uplift, and a richer earnings multiple tied to those projections.
Result: Fair Value of ¥4,146 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
Still, the bullish case for Daiichi Sankyo Company leans heavily on a few oncology blockbusters. As a result, any safety, pricing or patent setbacks could quickly weaken that story.
Find out about the key risks to this Daiichi Sankyo Company narrative.
Next Steps
If the mix of optimism and concern around Daiichi Sankyo Company feels familiar, use it as a prompt to move fast and test the numbers yourself. Start by weighing both the upside potential and the risk flags through the 2 key rewards and 2 important warning signs.
Looking for more Daiichi Sankyo Company investment ideas?
If Daiichi Sankyo Company has sharpened your focus, do not stop here. Use fresh screeners to pressure test your thinking and spot opportunities others might ignore.
- Target resilient cash generators by scanning companies that combine steady fundamentals with strong balance sheets through the list of solid balance sheet and fundamentals (19 results).
- Hunt for quality at a discount and compare Daiichi Sankyo Company with businesses that score well on both valuation and fundamentals using the 17 high quality undervalued stocks.
- Explore potential income streams by reviewing companies that offer robust payouts through the 19 dividend fortresses.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com